Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | TYK2 | P29597 | 8/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 7/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | KIT | P10721 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | HSF1 | Q00613 | 2/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247753 | 0.83 | JAK1 (0.38) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247484 | 0.83 | JAK1 (0.38) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247547 | 0.83 | BRAF (0.40) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247362 | 0.83 | TYK2 (0.41) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247672 | 0.81 | TYK2 (0.36) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247575 | 0.81 | TYK2 (0.38) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247462 | 0.80 | TYK2 (0.37) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247715 | 0.80 | TYK2 (0.37) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247569 | 0.80 | TYK2 (0.37) | JAK1TYK2TNNI3KBRAFJAK2 | |
| SCHEMBL31247458 | 0.75 | GCK (0.46) | JAK1TYK2TNNI3KJAK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | JAK1 9/4885TYK2 1/4885TNNI3K 260/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | JAK1 5/4885TYK2 1/4885TNNI3K 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.